A recent study provided evidence, through the analysis of prostate organoids, that CHD1 loss drives prostate tumorigenesis by modifying AR binding at the level of lineage-specific enhancers and, particularly, shifts AR chromatin occupancy to trigger HOXB13-directed oncogenic transcription, in a context also dependent on the function of other tumor suppressors [614]. This evidence concerns the gene AR and neoplasm.